1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Aduhelm May Not Be Perfect, But It May Be A Start – If Patients Can Access It

Debate At CTAD Underscores Doctors’ Dilemma

 
• By Mandy Jackson

The Biogen/Eisai drug may have a disease-modifying impact on Alzheimer’s progression but the lack of published evidence is still causing prescriber reluctance and hampering reimbursement decisions.

Doctor viewing patient's brain scan on digital tablet in laboratory
Academic doctors may be able to inform initial Aduhelm treatment decisions • Source: Alamy

Neurologists at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting conceded that the mixed Phase III results for Biogen, Inc./Eisai Co., Ltd.’s Aduhelm (aducanumab) complicate decisions about whether to prescribe the drug. However, they also suggested that Aduhelm as is the first and only potentially disease-modifying therapy approved in the US for Alzheimer’s disease, ongoing debates around safety and efficacy should not prevent doctors from trying the medicine in patients with no other options.

A 9 November roundtable discussion of the US Food and Drug Administration’s accelerated approval of Aduhelm in June underscored the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Neuphoria To Look At Strategic Options After BNC210 Fails In Social Anxiety

 
• By Alaric DeArment

Neuphoria said that its Phase III trial of BNC210 in social anxiety disorder did not meet the primary or secondary endpoints, but its PTSD program will continue.

Viatris Looks To Expand Japan Presence With Aculys Acquisition

 
• By Lisa Takagi

Global generics-focused giant acquires Japanese venture with late-stage, two-asset CNS pipeline as it looks to build presence in Japan.

Praxis Has Unexpected Hits In Two Phase II Essential Tremor Studies

 
• By Joseph Haas

Praxis hopes to file ulixacaltamide for approval early next year, with a goal of joining a generic beta blocker as the only approved therapy for the movement disorder.

Cash Bonanza For European Oncology-Based Biotechs

 
• By Kevin Grogan

Adcytherix and Step Pharma join Tubulis in raising funds for their cancer drug projects.

More from Therapy Areas

Summit Presses Ahead With Ivonescimab Filing Despite Approval Doubts

 
• By Andrew McConaghie

Frontrunner believes it can gain a first approval in EGFR+ lung cancer, even though the FDA recently raised the bar on overall survival.

Neuphoria To Look At Strategic Options After BNC210 Fails In Social Anxiety

 
• By Alaric DeArment

Neuphoria said that its Phase III trial of BNC210 in social anxiety disorder did not meet the primary or secondary endpoints, but its PTSD program will continue.

ESMO 25: Ovarian Cancer Data Validates Tubulis ADC Platform

 
• By Kevin Grogan

Positive first-in-human data for TUB-040 represent "a momentous milestone" for the German biotech, according to its CEO Dominik Schumacher.